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List of acronyms and abbreviations: 
Term Abbreviation 
PCOS Polycystic ovary syndrome  
AMH Anti-Müllerian Hormone 
LH Serum Luteinizing Hormone  
FSH Follicle stimulating Hormone 
LH/FSH Luteinizing Hormone to Follicle stimulating Hormone 
ratio 
FSH/LH Follicle stimulating Hormone to Luteinizing Hormone 
ratio 
MIS  Müllerian Inhibiting substance 
HA Hyperandrogenic anovulation 
NIH National Institute of health 
FNPO Follicle number per ovary 
BMI Body mass index 
GnRH Gonadotrophin releasing hormone 












Polycystic ovary syndrome (PCOS), a heterogeneous disorder of unclear etiology, is 
an important cause of   both ovulatory and menstrual irregularity and androgen 
excess in women. In PCOS, the ovary doesn't make all of the hormones it needs for 
an egg to fully mature. The follicles may start to grow and build up fluid but 
ovulation does not occur instead it remain as cysts.  
The objective of this study is to assess serum gonadotrophins in relation to anti-
Müllerian hormone in polycystic ovary syndrome. 
The study was carried out in 2 Fertility Centers at Khartoum State, at the University 
of Khartoum fertility center (U.K.F.C) (Saad Abu Alela hospital) and   Dr. Elsir Abu EL 
hassan fertility center; during the period from December 2017 to March 2018. 
Ninety nine Patients with PCOS were included in the study .Their ages range 
between less than 22 to above 32 years and thirty matched normal individuals were 
taken as control group, and were tested for serum Gonadotrophins (Follicle 
stimulating hormone (FSH), luteinizing hormone (LH)) and anti-Müllerian hormone 
(AMH) Levels. 
The serum values of FSH in normal subject were higher (9.19+_0.66) than in patients 
with PCOS (6.46+_0.20), while the patients with PCOS were higher than normal 
subjects in the LH (9.21ng/ml), AMH (8.74ng/ml) levels . 
The FSH/LH ratio in normal subjects was higher (1.49 ng/mL) than patients with 
PCOS (0.98 ng/mL). While the patients with PCOS were higher LH/FSH ratio(1.48 





FSH concentration correlated significantly (0.316) and positively (P<0.01) with LH of 
the patients with PCOS and FSH/LH and LH/FSH of the normal subjects. The highest 
correlation coefficient was found between LH and LH/FSH in patients with PCOS 
followed by the negative correlation coefficient of FSH/LH and LH/FSH in patients 
with PCOS. Moreover, the association between AMH and FSH/ LH was significantly 
(0.246) negatively (P<0.05) correlated in the patients with PCOS. 
There was no significant difference in serum hormones concentration between 
different age groups being studied. 
There was no significant difference in the concentration of hormones in the serum 




















يعىبرررك و ررربش ض مبرررتيا نررركث نىبرررتيي يورررةي  وصررربتأل ببرررك مضاررروم م ررر    ررر  ضوصررربتأل  عرررة  ض ى رررت    
ض  ضرررتت يو ررربش ض مبرررتيا يررر ن  ض ررر   ةمض رررةمال ض يرررزكيم مايرررتنل ض زكن  رررتن ض   كيرررم ع ررر  ض ىببرررباعملبررر  
 عررة  وعرر بل  ررا ض زكن  ررتن ض ىررض ووىتضزررت ض ب ييررم  ل يرر َ ض  تنررا  بررً  وبررة  ض و يعرر ن  ررض ض  مررر 
 موعزا بت ض ضئا   ي عملبم ض ىبببا ال ووةي موبقض  أ بتسي
قبررتس ض زكن  ررتن ض مومررزل  لمبررتيا منعك رر  نررة  ع قىزررت نررل نيررتن  كنرر    ض زررةن نرري  رر   ض ةاضصررم
 نبلك  ض  ت م نكث و بش ض مبتياي
 ررر   ض ةاضصرررم  ضكيرررره  رررض نك رررزيي  ل عرررر بم مض عقررر   ررررض ماليرررم ض  ك ررر   نك ررررز ضتنعررر  ض  ك رررر     
عرر بم مض عق تنضىيرررمض صرررعة  بررر  ض عرر و منك رررز ض ضررك  بررر  ض وضررري  ل عرر بم مض عقررر   ررر   ض مىررركل نررري  ل 
 ي7102ض ض نتاس 7102نيضمبك 
ض ةاضصرررم وضرررل موضرررع   نكييرررم بى ررربش ض مبرررتيا مٌ ٌررر    ضرررتت صرررلبمتن  يرررتب   لةاضصرررم  ويرررم ه  
زكن  ررررتن ض مومررررزل ض  وك بررررز صرررر م  قرررربش  27صرررر م أ رررر    ٍررررك نرررري 77ي  عمررررتا   وىرررركضمل برررربي  قررررا نرررر 
 منيتن  كن   نبلك  زييتض زكن   ض مومز  لو يعلم,ض زكن   ض م ي   لجض  ضوصمكو  لمبتيا
نررري  ) 1100 ±9109زكنررر   ض مومرررز  لو يعرررلم  رررض ض  ضرررتت ض ضرررلبمتن  رررت   علررر  ت ل  ض قرررب  ض معرررلبم 
 م  ت  ضكض /نررراو 9170تزكنررر   ض م يررر   لجضررر  ضوصرررمك   ررري  ضررربم ض ) 1171± 01.0(نكييرررتن ض ى ررربش 
 يبت ى بش ت  ضكض /ناو وك بز مت ضعلض ع ة ض مكييتن 212نيتن  كن   نبلكت 
ض  رررض ض ورررتالن ض  ببعبرررم  علررر  ضوصرررمكض  ضررربم بررربي ض زكنررر   ض مومرررز  لو يعررلم مض زكنررر   ض م يررر   لجضررر  
 ت  ضكض /ناويبب مررررررررت نكييررررررررتن ض ى رررررررربش 1192تبررررررررت ى بش  ت  ضكض /نرررررررراو نرررررررري ض مكييررررررررتن 01.9ت
مض زكنررررر   ض مومرررررز  ضوصرررررمك ت  ضكض /نرررررا و رررررض ض  ضررررربم بررررربي ض زكنررررر   ض م يررررر   لجضررررر   01.2 ت علررررر
  ي ت  ضكض /ناو 1122 لوتالن ض ضلبمم ت بت  ضبم لو يعلم 
نررررل ض زكنرررر    و 1110ضقررررا نرررري  تو من ضبررررم  11200ت  زكنرررر   ض م يرررر   لو يعررررلم  رررر  ع قررررم  ببرررركل ض  
ض  ضرررربم برررربي ض زكنرررر   ض م يرررر   لو يعررررلم مض زكنرررر    ييررررت نررررل م  يرررر   لجضرررر  ضوصررررمك  لمكييررررتن ض م
مض  ضرربم برربي  ضوصررمكبرربي ض زكنرر   ض م يرر   لجضرر   ي ضررة  لضررلبمتني عل  ضاوبررت  ض م يرر   لجضرر  ضوصررمك
بررربي  ض زكنررر   ض م يررر   لو يعرررلم ض مكييرررتن نىب عرررت بع قرررم صرررلببم ض زكنررر   ض م يررر   لجضررر  ضوصرررمك م 
  ض م يررر   لجضررر  ضوصرررمك م ضررربم ض زكنررر   ض م يررر   لجضررر   ضررربم ض زكنررر   ض م يررر   لو يعرررلم مض زكنررر 
 ضوصمك مض زكن   ض م ي   لو يعلم  لمكييتني
برربي نيررتن  كنرر   نبلررك م و117.0بيرر ا  ببرركت  و   1ي 15تضقررا نرري و ضررة ع قررم صررت بم عرر مل علرر    رر  
ي ضررررة ي مال   لمكييررررتن ض  ضرررربم برررربي ض زكنرررر   ض م يرررر   لو يعررررلم مض زكنرررر   ض م يرررر   لجضرررر  ضوصررررمك 
 ض ى ن ببي  ضبم ض زكن  تن ض ٍ ي  ض ن ىلف ض مئتن ض عمكيمي 
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Polycystic ovary syndrome (PCOS), a heterogeneous disorder of 
unclear etiology, is an important cause of both ovulatory and menstrual 
irregularity and androgen excess in women [1, 2]. 
 Polycystic ovary syndrome is a serious condition resulting in ovaries which 
cannot ovulate an oocyte. Polycystic ovaries are the main cause of infertility 
in women. [3] women with PCOS, have  ovaries that don't  make all of the 
hormones it needs for an egg to fully mature. The follicles may start to grow 
and build up fluid but ovulation does not occur. Instead, some follicles may 
remain as cysts. For these reasons, ovulation does not occur. [3] 
When fully expressed, the manifestations include ovulatory dysfunction, 
androgen excess and polycystic ovaries. It is recognized as one of the most 
common endocrine/metabolic disorders of women. This syndrome was first 
described by Stein and Leventhal in 1935 who described seven women 
suffering from amenorrhea, hirsutism, and enlarged ovaries with multiple 
cysts[4],although the presence of sclerocystic ovaries had been recognized 
for at least 90 years prior to their report[1]. 
In the 1990s, two new aspects of PCOS became apparent. First, in many 
instances polycystic ovaries are inherited and this could be through either 
the mother or father. The polycystic ovary, therefore, can be considered 
part of an individual's genetic makeup and remains so for life. The 
symptoms of PCOS however, may change at different times of life [5] 





endocrine disorders. The wide range and frequency of symptoms made it 
difficult to establish a consistent clinical picture. [6]  
 Polycystic ovary syndrome (PCOS) also called hyperandrogenic anovulation 
(HA) [11] or Stein-Leventhal syndrome.[4] Women with PCOS may have 
enlarged ovaries that contain small collections of fluid – called follicles- 
located in each ovary as seen during an ultrasound examination. It is 
thought to be one of the leading causes of female sub-fertility [7, 8, 9] and the 
most frequent endocrine problem in women of reproductive age [10]. 
PCOS is associated with various endocrine abnormalities such as increased serum LH 
level relative to FSH release Because of the pulsatile nature of their release; a single 
test fails to detect an increase ratio of LH: FSH and increase serum testosterone. LH 
is sufficient to cause anovulation. Estimation of these hormones aids in the 
diagnosis of PCOS [12, 13]. 
However, there is a considerable inter individual variation in presentation. Major 
hormonal studies include estimation of AMH, FSH, and LH in serum. 
 Luteinizing hormone in both sexes stimulates secretion of sex steroids from the 
gonads. In the tests, it stimulates the synthesis and secretion of testosterone.  
The ovaries respond to LH stimulation by secretion of testosterone, which is 
converted into estrogen by adjacent granulosa cells. LH is required for continuous 
development and function of corpora lutea. The name luteinizing hormone was 
derived from this effect of inducing luteinization of ovarian follicles. 
Follicle-stimulating hormone (FSH) stimulates the maturation of ovarian follicles and 
critical for sperm production. It supports the function of Sertoli cells, which in turn 
support many aspects of sperm cell maturation. Traditionally the level of LH and 





AMH also known as Müllerian Inhibiting Substance (MIS) is a new diagnostic marker 
of ovarian function. The level of AMH increased in PCO patients, and may become 
part of its diagnostic criteria. [14.15] AMH levels correlate well with the ovarian antral 
follicle count and were the only levels that decreased longitudinally over time 
compared with FSH, estradiol, and inhibin-B levels. AMH levels do not vary 
significantly during the menstrual cycle and can therefore, be drawn on any day of 
the cycle. 
1.2. Justification: 
  Polycystic ovarian syndrome (PCOS) is very common among women of 
reproductive age. The lack of well-defined diagnostic criteria makes identification of 
this common disease confusing to many clinicians. Also, the varied manifestations of 
the disorder, the estimation of serum gonadotrophins and anti-Müllerian hormone 
in the PCOS patients often will vary over time as the patient enters different stages 
of life with different goals. 
According to our knowledge there is scarcity informations about PCOS in Sudan. 











1.3.1 General objectives: 
 To assess serum gonadotrophins in relation to anti-Müllerian hormone 
in polycystic ovary syndrome patients attended University of Khartoum 
fertility center (U.K.F.C) (Saad Abu Alela Hospital )and Dr.Alsir Abu  elhassan 
fertility center.  
 
 1.3.2 Specific objectives:  
• To estimate serum luteinizing hormone (LH) concentration (ng/ml).   
• To estimate serum follicle stimulating hormone (FSH) concentration 
(ng/ml).  
• To compare serum luteinizing hormone to follicle stimulating hormone 
Ratio (ng/ml). 












2. Literature review: 
2.1 Pathophysiology of Ovaries:  
The ovaries are female gonads. Paired oval, each of them about 2-3 cm, the 
size and appearance of the ovaries depend on both age and the stage of the 
menstrual cycle. In the young adult they are almond shaped, solid, grayish pink and 
approximately 3 cm long, 1.5 cm wide and 1 cm thick. In the child, the ovaries are 
small structures, approximately l.5 cm long. They have a smooth surface and at birth 
contain between 1 and 2 million primordial follicles, some of which will ripen into 
mature follicles in the reproductive years. The ovaries increase to adult size in the 
months preceding puberty. This considerable increase is brought about by 
proliferation of the stromal cells and by the commencing maturation of the ovarian 
follicles. After the menopause, no active follicles are present and the ovary becomes 
a small, shrunken structure with a wrinkled surface. The ovary is the only intra-
abdominal structure not to be covered by peritoneum. Each ovary is attached to the 
cornu of the uterus by the ovarian ligament and at the hilum to the broad ligament 
by the mesovarium, which contains its supply of vessels and nerves. Laterally, each 
ovary is attached to the suspensory ligament of the ovary with folds of peritoneum 
which becomes continuous with that overlying the psoas major. Anterior to the 
ovary lie the Fallopian tubes, the superior portion of the bladder and the 
uterovesical pouch. The ovary is bound behind by the ureter where it runs 





 The surface of the ovaries is covered by a single layer of cuboidal cells, the germinal 
epithelium. Beneath this is an ill-defined layer of condensed connective tissue, the 
tunica albuginea, which increases in density with age. At birth, numerous primordial 
follicles are found, mostly in the cortex, but some are found in the medulla. With 
puberty, some form each month into Graafian follicles, which, at later stages of their 
development, form corpora lutea and ultimately atretic follicles, the corpora 
albicans. [46] 
Polycystic ovary syndrome (PCOS) is one of the outstanding matters of 
endocrinological and gynecological investigation due to its complex pathogenesis 
and its multiple clinical expressions. PCOS are the most common endocrine disorder 
in reproductive age women and affect approximately 7-12% of this population 
worldwide [47]. Most recent research supports the opinion that androgen excess is a 
prerequisite diagnostic criterion for PCOS [48].  
2.2 Pathogenesis: 
Polycystic ovaries develop when the ovaries are stimulated to produce 
excessive amounts of male hormones (androgens), particularly testosterone by 
either release of excessive luteinizing hormone (LH) by the anterior pituitary gland 
or through high levels of insulin in the blood (hyperinsulinaemia) in women whose 
ovaries are sensitive to this stimulus. [16, 17] Along with that reduced levels of sex-
hormone binding globulin can result in increased free androgens. 
Pre- antral and small antral follicles produce AMH six times the density of pre-antral 
follicles compared with the normal ovary in PCOS.[18] High AMH levels in PCOS also 





Possible role of AMH in the pathophysiology of PCOS is through its counteraction on 
FSH in promoting follicular growth. [20] The size of the 2-5 mm follicle pool is an 
independent and important contributor to the follicular arrest of PCOS. [21] 
The majority of patients with PCOS has insulin resistance and/or are obese. Their 
elevated insulin levels contribute to cause the abnormalities seen in the 
hypothalamicpituitary-ovarian axis that lead to PCOS. Hyperinsulinemia increase 
GnRH pulse frequency, LH over FSH dominance, increased ovarian androgen 
Production [17], decrease follicular maturation, and insulin resistance is a common 
finding among patients of normal weight as well as overweight patients.[23,22] 
Many cases of PCOS are characterised by a complex positive feedback loop of insulin 
resistance and Hyperandrogenism. In most cases it cannot be determined which of 
those two should be regarded causative. Experimental treatment with either 
antiandrogens or insulin sensitizing agents improves both hyperandrogenism and 
insulin resistance. 
2.3 PCOS and associated complications: 
 Having polycystic ovary syndrome may make a series of conditions more 
likely, like type 2 diabetes, high blood pressure, cholesterol and lipid abnormalities, 
metabolic syndrome, non-alcoholic steatohepatitis, infertility, sleep apnea, 
depression and anxiety, abnormal uterine bleeding, cancer of uterine lining, 
gestational diabetes or pregnancy- induced high blood pressure especially if obesity 
also is a factor. [24] 
Untreated polycystic ovary syndrome may be regarded as a disorder that progresses 
until the time of menopause. On-going studies lend support to the hypothesis that 





cardiovascular disease. [25] Because the syndrome is also associated with lipid 
abnormalities, affected women could benefit from measures to prevent 
cardiovascular disease and the other sequel of longstanding hypertension and 
diabetes mellitus that are associated with the syndrome. 
More important, the long-term effects of unopposed estrogen place women with 
the syndrome at considerable risk for endometrial cancer, endometrial hyperplasia 
and, perhaps, breast cancer. [26, 27] The risk of endometrial cancer is three times  
higher in women with polycystic ovary syndrome than in normal women. In 
addition, small observational studies have suggested that chronic anovulation 
during the reproductive years is associated with a three to four times increased risk 
of breast cancer in the postmenopausal years. 
2.4 Role of gonadotrophins in PCOS: 
follicle stimulating hormone (FSH) and luteinizing hormone (LH) are 
gonadotropins, hormones made in and released from pituitary gland that control 
the function of gonads, testes and ovaries, The absolute level of each, as well as the 
LH: FSH ratio, can offer significant insight into the PCOS patient[28] .The ratio of LH to 
FSH (follicle stimulating hormone), when measured in international units, is greater 
than 1:1[28], as tested on day 3 of the menstrual cycle. A higher level of LH than FSH 
in the early part of the menstrual cycle is a hallmark of PCOS. Clearly increased LH is 
related to, if not diagnostic of, PCOS. Elevation in LH is very useful in diagnosis of 
PCOS. The measurement of FSH will also permit the diagnosis of an occult ovarian 
failure where the FSH levels are particularly elevated. [29] 
Women with PCOS have higher GnRH, which in turn results in an increased in 





detect an increase ratio of LH: FSH and increase serum testosterone. LH is sufficient 
to cause anovulation. [30]  
2.5 Role of antimüllerian hormone (AMH) in PCOS: 
AMH is a glycoprotein growth factor and a member of the transforming 
growth factor super family (TGF-B) with a molecular weight of 140kDa. AMH also 
known as Müllerian Inhibiting Substance (MIS) is a new diagnostic marker of ovarian 
function.This hormone is made in the testes of men. However, now we know that in 
female neonates, AMH is virtually undetectable but increases gradually until 
puberty and remains relatively stable thereafter, and throughout the reproductive 
period. [31] 
 AMH has an integral role in the intrauterine development and sex differentiation of 
the male fetus. It is secreted from the Sertoli cells of the developing testes inhibiting 
ipsilateral mullerian duct development and thereby allowing the Wolffian duct 
system to prevail [32]. In female, Anti-Müllerian hormone (AMH) is produced by the 
granulosa cells of the recruited follicles until they become sensitive to FSH. AMH has 
been identified as a regulator of the recruitment, preventing the depletion of all 
primordial follicle pool at once. It is primarily produced by the pool of early-growing 
follicles, which are believed to serve as a proxy for the number of primordial follicles 
in the ovary. It is widely accepted that the reduction of AMH levels in serum is the 
first indication of a decline in the follicular reserve of the ovaries. AMH 
concentration remains stable throughout the menstrual cycle. [34] 
 However, the role of AMH across the female reproductive life-span has only more 
recently come to light [33]. In the ovary, AMH has an inhibitory effect on primordial 
follicle recruitment as well as on the responsiveness of growing follicles to FSH and 





however, that follicle number only added 5.3% to variance in the concentration of 
AMH, and raised production of hormone is an intrinsic property of granulosa cells in 
PCOS [35, 36. 37]. The ovary-specific expression pattern in granulosa cells of growing 
non selected follicles makes AMH an ideal marker for the size of the ovarian follicle 
pool and also a prognostic factor for fertility potential [32]. 
Women with PCOS have an increased number of small follicles in the pre-antral and 
antral stage, and therefore, it is observed that their AMH serum concentrations are 
higher than their counterpart [33]. first reported this in 1997, there have been several 
clinical studies that have confirmed the increased levels of serum AMH levels (two 
to three times) higher in PCOS compared with the levels in women with normal 
ovaries. Another study reported significantly elevated levels of AMH in 
normogonadotrophic, normoestrogenic, an-ovulatory patients compared with 
controls [32]. 
2.6 Previous studies: 
Early studies have shown that in women with Polycystic Ovary Syndrome 
(PCOS) both serum and follicular fluid AMH levels are significantly higher compared 
to controls [38]. Recent studies have confirmed the latter results [39] suggesting that 
the increased in AMH levels in women with PCOS is related to the large number of 
small diameter (2–5 mm) follicles [40]. The ovarian morphology of women with PCOS 
is characterized by the presence of a two- to six-fold increase in the ovarian 
follicular number (preantral and small antral follicles) [40, 41], most probably due to 
hyperandrogenemia [42]. In anovulatory women with PCOS, a suspension of follicular 
development occurs when the diameter of the follicles ranges from 6–9 mm, just 





serum AMH levels in women with PCOS are related, most probably, to the follicular 
arrest that suspends the selection of the dominant follicle. 
In young women with PCOS and in young normal ovulatory women, who served as 
controls, serum AMH levels did not correlate with serum FSH levels. On the 
contrary, serum AMH levels were positively correlated with LH levels in women with 
PCOS (r = 0.414. p < 0.001). The increased serum LH levels were the most significant 
conjunction between ovulation disorders that characterize PCOS, and high serum 
AMH levels [39]. 
In addition, women with classic PCOS (1990 NIH-diagnostic criteria) [44] presented 
significantly higher LH and LH/FSH ratio. 
 In conditions of increased LH and normal to low FSH, such as in PCOS, AMH serum 
levels are increased and tend to be associated to serum LH, while in conditions of 
increased FSH such as premature ovarian failure, AMH serum levels are decreased 
and tend to be associated to serum FSH in young PCOS women with 
hyperandrogenemia. Serum AMH levels are linked to serum LH levels, reflecting 
follicle overstimulation. The evidence that supports the theory of a link between 
AMH and LH in PCOS comes from both in vitro and in vivo experiments. Serum AMH 
levels have been directly linked to serum LH levels in the most severe forms of 
PCOS. LH has also been shown in vitro to directly increase serum AMH levels in PCOS 
derived granulosa cells. Finally, hyperandrogenism, obesity, insulin resistance and 
Oral contraceptive (OCs) administration, indirectly affect serum AMH levels, by 
modulating serum LH. Concerning PCOS, AMH correlation to LH can be used in the 
future for the assessment of the severity of PCOS, of the amelioration of PCOS 
under Oral contraceptive (OCs) treatment, as well as of the efficacy of infertility 





implications of the theoretical approach that serum AMH levels are modulated by 
both gonadotropins might become important in clinical practise in a variety of 
medical conditions. For instance, serum AMH levels might be used in the future as a 
marker of cysts formation in the ovaries [45] as well as of ovarian endometriosis, or 
as a marker of ovarian response to treatment of ovarian cysts or ovarian 
endometriosis by oral contraceptives or surgery. Additionally, new insights 
concerning the impact of AMH in normal pubertal development [46]with clinical 
implications in the treatment of infertile women with hypothalamic amenorrhea 





















3. Material and methods 
3. 1.Material 
3.1.1 Study design: 
Cross-sectional study was conducted in Sudanese women with polycystic ovary 
syndrome (PCOS). 
3.1.2 Study area:  
This study was carried out in 2 Fertility Centers at Khartoum State, at the University 
of Khartoum fertility center (U.K.F.C) (Saad Abu Alela hospital) and   Dr. Elsir Abu EL 
hassan fertility center; during the period from December 2017 to March 2018. 
3.1.3 Study subjects: 
Patients who have PCOS ninety nine patients and thirty normal females as control 
measurement of were tested for serum gonadotrophins FSH, LH and anti-Müllerian 
hormone (AMH) Levels. The inclusion criteria included Sudanese women patients 
with polycystic ovary syndrome PCOS of all ages. And exclusion criteria rejected 
patients with heavy polycystic ovary syndrome PCOSH. 
3.2 Data collection and clinical assessment: 
3.2.1 Interview and questionnaire: 
Interview with the patients was carried out to obtain the clinical data. A 
questionnaire was specifically designed to obtain information which helped in either 
including or excluding certain individuals in or out from the study. 
3.2.2 Sample size:  
Ninety nine patients with PCOS (test group) and 30 normal females (control group) 






3.2.3 Blood samples collection: 
5ml of venous blood were collected after disinfection with 70% alcohol using plane 
vacutainers often having their consent. 
3.3 Methods: 
3.3.1 Biochemical methods: 
 Blood samples were obtained by venipuncture on day 2-3 of the menstrual period. 
The serum FSH and LH levels were measured by Automated  Enzyme Immunoassay  
System TOSOH (model AIA 360). 
AMH was Measured by HumaReader HS using the AMH Gen II, Bekman Coulter 
enzyme linked immunosorbent assay (ELISA) kits. 
3.3.2 Background to Automated Enzyme Immunoassay System 
TOSOH (model AIA 360): 
3.3.2.1 Instrumentation: 
Automated   Enzyme Immunoassay  System TOSOH (model ALA 360) instrument is 
basically a spectero photometer .it consists of a display and an Operation Panel , 
Carousel unit for reagent cup holder and the sample holder, it rotates the specimen 
and reagent cups  ,Substrate Compartment ,this is used for the enzyme substrate 
bottle and the disinfect ethanol solution bottle. In the outside Printer Unit and 
Bottle Tray where the diluents, wash solution, waist fluid and disinfecting ethanol 
bottles are stored. 
3.3.2.2   The principle: 
Automated   Enzyme Immunoassay  System  (TOSOH ) technique for gonadotrophins 





and LH in samples by Fluorometric enzyme immunoassay (FEIA)  using A ready-to-
use “all-in-one” test cup  which consist of aluminum  top seal , lyophilized  conjugate  
and  magnetic beads  coated  with  immobilized  antibodies/antigens . The  substrate 
and fluorescence kinetic detection to give the concentration of gonadotrophins in 
sample. 
3.3.3 Background to HumaReader HS: 
3.3.3.1 Instrumentation: 
The HumaReader HS is a microprocessor-controlled, general-purpose photometer 
system designed to read and calculate the results of ELISA assays in micro titer plate. 
All human methods are preprogrammed and multiple calculations are available 
.They consist of power pilot lamp ,touch panel to Display program and  plate carrier 
and amicro plate. 
3.3.3.2 Principle: 
The HumaReader HS technique for AMH measurement   using the  AMH Gen II ELISA 
kits which is an enzymatically amplified two-site immunoassay. The degree of 
enzymatic turnover of the substrate is determined by dual wavelength absorbance 
measurement   at 450 nm and between 600 and 630nm. The absorbance measured 
is directly proportional to the concentration of AMH in the samples. A set of AMH 
calibrators is used to plot a calibration curve of absorbance versus AMH 
concentration. The AMH concentration in the samples can then be calculated from 






3.3.3.3 Material and reagents: 
All materials and reagents used in this study were of analytical grade: 
1-Ab PLATE consists of Anti-AMH Gen II Antibody Coated Microtitration strips, the 
microtitration wells with mouse monoclonal anti-AMH IgG Immoblized to the inside 
wall of each well. AMH GenII Sample DILUENT: One bottles ,13 ml ,containing buffer 
with bovine serum albumin (BSA)<O.5 %PRO*300and sodium azide. 
2-BIO_ CON_J RTU: AMH Gen II antibody-Biotin Conjugate: One bottle,13 ml 
containing biotinylated anti-AMH antibody in buffer with protein (bovine 
,mouse)<0.3% Pro Clin 300 and sodium azide. 
3-STERP-CONJ-RTU: Sterptavidin-Enzyme Conjugate: One bottle,13 ml, containing 
streptavidin –HRP in buffer with protein (mouse,fish) and<10% methanol. 
4-ASSAY-BUFFER: AMH GenII Assay Buffer: Two bottle, 13ml, containing buffer with 
BSA ,protein ,<0.3% proClin 300 and sodium azide. 
5- TMB SOLN: TMB Chromogen Solution :One bottle,11 ml  containing a solution of 
TMB in citrate buffer with hydrogen peroxide. 
6- WASHCON I: Wash Concentrate I: 100 ml , containing buffered saline with a 
nonionic detergent. 
7-STOP-SOLN-A: Stopping Solution A: 0.2 M sulfuric acid. 
3.3.3.4   Preparation of Reagents: 
1-Wash Solution: Dilute 1 part Wash Concentrate 1 with 9 parts deionized water. 
2-Microtitration Wells: Select the number of coated wells required for the assay. 
3.3.3.5 Sample preparation: 
For the determination of serum AMH the calibrators   , controls and samples are 





After incubation and washing, anti-AMH detection antibody labeled with biotin is 
added to each well. After a second incubation and washing step, streptavidin- 
horseradish peroxidase (HRP) is added to the wells. After a third incubation and 
washing step, the substrate tetramethylbenzidine (TMB) is added to the wells. Lastly 
an acidic stopping   solution is added. The AMH concentration in the samples can be 
calculated from the calibration curve of absorbance versus AMH concentration. 
3.4 Ethical consideration: 
 Written consent was obtained from Ethical Committee – International 
University of Africa. 
 The objectives of the study were explained to all individuals participating 
in this study. 
3.5 Data analysis: 

















This study aimed to investigate the serum gonadotrophins and   anti-
Müllerian hormone levels in patients with polycystic ovary syndrome, so as to find a 
correlation to either reinforce or refute any claims of relationship between them as 
a diagnostic or screening tool. 
The study targeted 99 patients with PCOS and 30 healthy persons. 
Table 1. Serum hormones concentration in normal and 







FSH (ng/mL) 9.19±0.66 6.46±0.20 0.000 
LH (ng/mL) 6.80±0.44 9.21±0.64 0.002 
AMH (ng/mL) 2.71±0.14 8.74±0.40 0.000 
FSH/LH 1.49±0.13 0.98±0.06 0.000 
LH/FSH 0.88±0.11 1.48±0.10 0.000 
 
 
Mean ± Standard error of mean 
 
 Table (1) showed the hormones concentration in the serum of normal and 
patients with PCOS, the results revealed highly significant (P<0.01) differences 
between patients with PCOS and control in all studied hormones. FSH in normal 
subjects was higher (9.19 ng/mL) than in patients with PCOS (6.46 ng/mL). While  
the patients with PCOS were higher than normal subjects in LH (9.21ng/ml) and 
AMH (8.74ng/ml). 
The FSH/LH ratio in normal subjects was higher (1.49 ng/mL) than patients with 
PCOS (0.98 ng/mL). While the patients with PCOS were higher LH/FSH ratio  (1.48 







Table 2. Association between studied hormones with each 
other in normal and patients with PCOS  
  FSH LH AMH FSH/LH LH/FSH 
FSH 
Normal 1     
Patients 1     
LH 
Normal 0.181 1    
Patients 0.316
**
 1    
AMH 
Normal -0.066 0.191 1   
























**= significant differences at P<0.01 
  *= significant differences at P<0.05 
      Table (2) FSH concentration correlated significantly (0.316) and positively 
(P<0.01) with LH of the patients with PCOS and FSH/LH and LH/FSH of the normal 
subjects. The highest correlation coefficient was found between LH and LH/FSH in 
patients with PCOS followed by the negative correlation coefficient of FSH/LH and 
LH/FSH in patients with PCOS. Moreover, the association between AMH and FSH/ LH 
was significantly (0.246) negatively (P<0.05) correlated in the patients with PCOS.  
Table 3. Serum hormones concentration in different age 
groups 
 
  Age (years)   





(n=28) P. value 
FSH 7.42±0.60 6.74±0.25 8.11±0.71 0.061 
LH 8.64±1.49 8.78±0.58 8.24±1.34 0.913 
AMH 8.65±1.09 7.63±0.47 5.86±0.75 0.095 
FSH/LH 1.05±0.13 1.06±0.07 1.25±0.12 0.404 
LH/FSH 1.20±0.22 1.41±0.10 1.16±0.17 0.393 
 





The results presented in table (3) indicated that, there was no significant difference 
in serum hormones concentration between different age groups being studied 
otherwise there were higher number of PCOS cases found in the age group 22-32 
(n=90) that means it is the main age range at which the women have high capacity 
in their reproductive system and the PCOS clear in them. 
 
Table 4. Serum hormones concentration in different geographical areas of 
the Sudan 
 










(n=10) P. value 
FSH 6.92±0.25 6.44±1.01 7.35±0.61 7.05±1.12 8.93±1.22 0.257 
LH 8.68±0.65 6.50±1.18 9.24±1.03 8.81±1.08 8.73±1.95 0.943 
AMH 7.40±0.43 9.98±2.67 4.56±0.93 8.15±1.67 6.54±1.07 0.200 
FSH/LH 1.10±0.07 1.11±0.25 0.92±0.17 0.94±0.15 1.49±0.33 0.313 
LH/FSH 1.34±0.10 1.12±0.27 1.35±0.22 1.55±0.31 1.18±0.31 0.868 
 
Mean ± Standard error of mean  
 
The results presented in table (4) clearly showed that there was no significant 
difference in the concentration of hormones in the serum of patients with PCOS, 
concerning the geographical areas of the Sudan. High numbers of PCOS cases were 
found in the central   part of Sudan, followed by   north, south and the low number 












This prospective study was conducted to evaluate the relevance of routine 
gonadotrophins (fsh ,lh)and AMH measurement in infertile females with PCOS.  
Table 1 & 2 in the current study we demonstrated the concentration of Serum 
hormones and Associated between them in normal and patients with PCOS 
indicated that there was highly significant differences (P<0.01) in all studied 
hormones. FSH in normal subjects was higher (9.19 ng/mL) than in patients with 
PCOS (6.46 ng/mL), while the patients with PCOS were higher than normal subjects 
in LH (9.21ng/ml) and AMH (8.74ng/ml) confirm those of previous studies [38, 39, 40 
,41,42,43,46] showing that AMH levels are 2- to 3-fold higher in women with PCOS 
compared to healthy women. The FSH/LH ratio in normal subjects was higher (1.49 
ng/mL) than patients with PCOS (0.98 ng/mL).While the patients with PCOS have 
higher in LH/FSH ratio (1.48 ng/ml) than the normal subjects, which are comparable 
with the results of previous studies [50, 51].  
FSH concentration correlated significantly (0.316) and positively (P<0.01) with LH of 
the patients with PCOS and FSH/LH and LH/FSH of the normal subjects. The highest 
correlation coefficient was found between LH and LH/FSH in patients with PCOS 
followed by the negative correlation coefficient of FSH/LH and LH/FSH in patients 
with PCOS. Moreover, the association between AMH and FSH/ LH was significantly 
(0.246) negatively (P<0.05) correlated in the patients with PCOS. Pigny et al [49] 
found no relationship between AMH, LH and LH\FSH in PCOS and controls While 






There was no significant difference in serum hormones concentration between 
different age groups being studied and. Pigny et al [49] found no relationship 
between AMH and age, LH and LH\FSH in PCOS and controls and there was no 
significant difference in the concentration of hormones in the serum of the subjects, 





















The prevalence of infertility is significantly high worldwide. Amongst the 
female infertility PCOS is an important cause and which must be correctly diagnosed 
for the effective treatment. Oocyte number and quality decline with age; however, 
fertility varies significantly even among women of the same age. Serum 
antiMüllerian hormone (AMH), is one of the hormone biomarker of follicle number 
has become known in recent years. [52] 
 In conditions of increased LH and normal to low FSH, such as PCOS, AMH serum 
levels are increased and tend to be associated to serum LH while in young PCOS 
women with hyperandrogenemia serum AMH levels are linked to serum LH levels, 
reflecting follicle overstimulation. The evidence that supports the theory of a link 
between AMH and LH in PCOS comes from both in vitro and in vivo experiments. 
Serum AMH levels have been directly linked to serum LH levels in the most severe 
forms of PCOS. LH has also been shown in vitro to directly increase serum AMH 
levels in PCOS derived granulosa cells. Finally, hyperandrogenism, obesity, insulin 
resistance and OCs administration, indirectly affect serum AMH levels, by 










5.3 Recommendations:  
 AMH correlation to LH could be used in the future for the assessment of the 
severity of PCOS, of the amelioration of PCOS under oral contraceptive (OCs) 
treatment, as well as of the efficacy of infertility treatment in clomiphene 
resistant women with PCOS.  
 Since serum AMH being more stable during the entire menstrual periods 
could be used as a better marker over FSH and LH for diagnosis of polycystic 
ovary syndrome especially where the ultra sonographic examination of the 
ovaries is not feasible. 
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